{"protocolSection":{"identificationModule":{"nctId":"NCT02119819","orgStudyIdInfo":{"id":"15062"},"secondaryIdInfos":[{"id":"2013-003552-21","type":"EUDRACT_NUMBER"},{"id":"I7I-MC-XNAA","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"OPKO Health, Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes","officialTitle":"Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes"},"statusModule":{"statusVerifiedDate":"2021-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-04"},"primaryCompletionDateStruct":{"date":"2015-08","type":"ACTUAL"},"completionDateStruct":{"date":"2015-10","type":"ACTUAL"},"studyFirstSubmitDate":"2014-04-17","studyFirstSubmitQcDate":"2014-04-17","studyFirstPostDateStruct":{"date":"2014-04-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-03-19","resultsFirstSubmitQcDate":"2021-03-19","resultsFirstPostDateStruct":{"date":"2021-04-14","type":"ACTUAL"},"dispFirstSubmitDate":"2015-12-23","dispFirstSubmitQcDate":"2015-12-23","dispFirstPostDateStruct":{"date":"2016-01-29","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-05-25","lastUpdatePostDateStruct":{"date":"2021-05-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"OPKO Health, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. All drugs will be given by an injection under the skin. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. Participants' involvement in the study is expected to last about 30 weeks.","detailedDescription":"The study will include a 12 week blinded treatment period, where neither the participant nor the investigator will know to which treatment each individual is assigned. Thereafter follows a 12 week period where participants and the investigator will know which treatment they are assigned to. Participants' on LY2944876 and on exenatide extended-release continue treatment in this period, those who received placebo will be followed without treatment."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"],"keywords":["Weight loss"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":420,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"10 mg LY2944876","type":"EXPERIMENTAL","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.\n\nParticipants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.","interventionNames":["Drug: LY2944876","Drug: Metformin"]},{"label":"15 mg LY2944876","type":"EXPERIMENTAL","description":"15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.","interventionNames":["Drug: LY2944876","Drug: Metformin"]},{"label":"30 mg LY2944876","type":"EXPERIMENTAL","description":"30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.","interventionNames":["Drug: LY2944876","Drug: Metformin"]},{"label":"50 mg LY2944876","type":"EXPERIMENTAL","description":"50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.","interventionNames":["Drug: LY2944876","Drug: Metformin"]},{"label":"Exenatide extended-release","type":"EXPERIMENTAL","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.","interventionNames":["Drug: Exenatide extended-release","Drug: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.\n\nParticipants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.","interventionNames":["Drug: Placebo","Drug: Metformin"]}],"interventions":[{"type":"DRUG","name":"LY2944876","description":"Administered SC","armGroupLabels":["10 mg LY2944876","15 mg LY2944876","30 mg LY2944876","50 mg LY2944876"]},{"type":"DRUG","name":"Exenatide extended-release","description":"Administered SC","armGroupLabels":["Exenatide extended-release"]},{"type":"DRUG","name":"Placebo","description":"Administered SC","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"Metformin","description":"Oral","armGroupLabels":["10 mg LY2944876","15 mg LY2944876","30 mg LY2944876","50 mg LY2944876","Exenatide extended-release","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","timeFrame":"Baseline, Week 12"}],"secondaryOutcomes":[{"measure":"Change From Baseline in HbA1c at Week 24","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","timeFrame":"Baseline, Week 24"},{"measure":"Percent Change From Baseline in Body Weight","timeFrame":"Baseline, Week 12; Baseline, Week 24"},{"measure":"Change From Baseline in Fasting Blood Glucose","description":"Least square means (LSM) was calculated from mixed-effects model with repeated measures (MMRM) analysis using restricted maximum likelihood (REML) with metformin use, baseline body mass index (BMI) category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.","timeFrame":"Baseline, Week 12; Baseline, Week 24"},{"measure":"Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values","description":"SMBG 7-point profiles were measured at morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. LSM were calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.","timeFrame":"Baseline, Week (Wk) 12; Baseline, Week 24"},{"measure":"Change From Baseline in Lipids","description":"Change from baseline in high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C). LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant an a random effect.","timeFrame":"Baseline, Week 24"},{"measure":"Change From Baseline in Fasting Fibroblast Growth Factor 21","description":"LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","timeFrame":"Baseline, Week 12; Baseline, Week 24"},{"measure":"Percentage of Participants Requiring Rescue Therapy","description":"Participants who received rescue medication with non-study antihyperglycemic medications or change their stable dose of metformin.","timeFrame":"Baseline through Therapy Completion (Week 24)"},{"measure":"Percentage of Participants Developing Anti-Drug Antibodies to LY2944876","description":"Percentage of participants developing anti-drug antibodies to LY2944876.","timeFrame":"Week 12 and Week 24"},{"measure":"Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2944876","description":"Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.","timeFrame":"Baseline, Week 8, Week 12, Week 16, Week 20, Week 24"},{"measure":"Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2944876","description":"Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.","timeFrame":"Baseline, Week 8, Week 12, Week 16, Week 20, Week 24"},{"measure":"Change From Baseline in Adiponectin Levels","description":"LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","timeFrame":"Baseline, Week 12; Baseline, Week 24"},{"measure":"Change From Baseline in Beta-Hydroxy Butyrate Levels","description":"LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","timeFrame":"Baseline, Week 12; Baseline, Week 24"},{"measure":"Change From Baseline in Glucagon Levels","description":"LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","timeFrame":"Baseline, Week 12; Baseline, Week 24"},{"measure":"Change From Baseline in Insulin Levels","description":"LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","timeFrame":"Baseline, Week 12; Baseline, Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women with diabetes mellitus Type 2\n* Have screening HbA1c ≥7.0% and ≤10.5% either on diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for 3 months prior to screening\n* Have body mass index (BMI) ≥23 and ≤45 kilograms per meter squared at screening\n\nExclusion Criteria:\n\n* Women of child bearing potential\n* Participants who have used thiazolidinediones within 3 months prior to screening, or any other drugs for treatment of hyperglycemia (except metformin) within the prior 2 months\n* Participants who have used insulin for diabetic control for more than 6 consecutive days within the prior year\n* Participants with impaired renal function (serum creatinine \\>124 micromole per liter (µmol/L) \\[1.4 milligrams per deciliter (mg/dL)\\] in women, \\>133 µmol/L \\[1.5 mg/dL\\] in men)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"John Muir Physician Network Clinical Research Center","city":"Concord","state":"California","zip":"94520","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"Valley Endocrine, Fresno","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"National Research Institute","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Desert Medical Group Inc","city":"Palm Springs","state":"California","zip":"92262","country":"United States","geoPoint":{"lat":33.8303,"lon":-116.54529}},{"facility":"Artemis Institute for Clinical Research","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Encompass Clinical Research","city":"Spring Valley","state":"California","zip":"91978","country":"United States","geoPoint":{"lat":32.74477,"lon":-116.99892}},{"facility":"Meridien Research","city":"Bradenton","state":"Florida","zip":"34208","country":"United States","geoPoint":{"lat":27.49893,"lon":-82.57482}},{"facility":"M & O Clinical Research, LLC","city":"Fort Lauderdale","state":"Florida","zip":"33316","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Suncoast Research Group, LLC","city":"Miami","state":"Florida","zip":"33135","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Suncoast Clinical Research","city":"New Port Richey","state":"Florida","zip":"34652","country":"United States","geoPoint":{"lat":28.24418,"lon":-82.71927}},{"facility":"Compass Research","city":"Oviedo","state":"Florida","zip":"32765","country":"United States","geoPoint":{"lat":28.67,"lon":-81.20812}},{"facility":"Clinical Research of Central Florida","city":"Winter Haven","state":"Florida","zip":"33880","country":"United States","geoPoint":{"lat":28.02224,"lon":-81.73286}},{"facility":"University of Hawaii","city":"Honolulu","state":"Hawaii","zip":"96813","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"East West Medical Institute","city":"Honolulu","state":"Hawaii","zip":"96814","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Rocky Mountain Diabetes and Osteoporosis Center","city":"Idaho Falls","state":"Idaho","zip":"83404","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"Iderc, P.L.C.","city":"Des Moines","state":"Iowa","zip":"50314","country":"United States","geoPoint":{"lat":41.60054,"lon":-93.60911}},{"facility":"Cotton O'Neil Diabetes and Endocrinology Center","city":"Topeka","state":"Kansas","zip":"66606","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"Mercy Medical Research Institute","city":"Springfield","state":"Missouri","zip":"65807","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"St John's Mercy Medical Center","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Mercy Health Research","city":"Washington","state":"Missouri","zip":"63090","country":"United States","geoPoint":{"lat":38.55811,"lon":-91.01209}},{"facility":"Southern New Hampshire Diabetes and Endocrinology","city":"Nashua","state":"New Hampshire","zip":"03063","country":"United States","geoPoint":{"lat":42.76537,"lon":-71.46757}},{"facility":"High Point Clinical Trials Center","city":"High Point","state":"North Carolina","zip":"27265","country":"United States","geoPoint":{"lat":35.95569,"lon":-80.00532}},{"facility":"Lillestol Research LLC","city":"Fargo","state":"North Dakota","zip":"58103","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"The Corvallis Clinic P.C.","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Blair Medical Associates, Inc.","city":"Altoona","state":"Pennsylvania","zip":"16602","country":"United States","geoPoint":{"lat":40.51868,"lon":-78.39474}},{"facility":"Texas Diabetes and Endocrinology","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Dallas Diabetes Endocrine Center","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"San Gabriel Clinical Research","city":"Georgetown","state":"Texas","zip":"78626","country":"United States","geoPoint":{"lat":30.63269,"lon":-97.67723}},{"facility":"Oakwell Clinical Research","city":"San Antonio","state":"Texas","zip":"78218","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Southwest Health Associates, P.A.","city":"Sugar Land","state":"Texas","zip":"77478","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"Wade Family Medicine","city":"Bountiful","state":"Utah","zip":"84010","country":"United States","geoPoint":{"lat":40.88939,"lon":-111.88077}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ampelokipoi","zip":"11527","country":"Greece","geoPoint":{"lat":37.75809,"lon":20.87248}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Thessaloniki","zip":"57010","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chihuahua City","zip":"31238","country":"Mexico","geoPoint":{"lat":28.63528,"lon":-106.08889}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guadalajara","zip":"44690","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tampico","zip":"89000","country":"Mexico","geoPoint":{"lat":22.28519,"lon":-97.87777}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bialystok","zip":"15-351","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gdansk","zip":"80-546","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gdynia","zip":"81-553","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lodz","zip":"90-242","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Poznan","zip":"61-853","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Szczecin","zip":"70-506","country":"Poland","geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Warsaw","zip":"01-518","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Manati Medical Center","city":"Manati","zip":"00674","country":"Puerto Rico","geoPoint":{"lat":18.42745,"lon":-66.49212}},{"facility":"American Telemedicine Center","city":"San Juan","zip":"00917-3104","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cluj-Napoca","zip":"400349","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Iași","zip":"700547","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ploieşti","zip":"100342","country":"Romania","geoPoint":{"lat":44.95,"lon":26.01667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Târgu Mureş","zip":"540098","country":"Romania","geoPoint":{"lat":46.54245,"lon":24.55747}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Timișoara","zip":"300456","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}}]},"referencesModule":{"references":[{"pmid":"30957581","type":"DERIVED","citation":"Park EJ, Choi J, Lee KC, Na DH. Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs. 2019 Jun;24(2):107-119. doi: 10.1080/14728214.2019.1604684. Epub 2019 Apr 19."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.\n\nThis access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks, plus background PO metformin."},{"id":"FG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks, plus background PO metformin.."},{"id":"FG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks, plus background PO metformin.."},{"id":"FG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks, plus background PO metformin.."},{"id":"FG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks, plus background PO metformin.."},{"id":"FG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks,plus background PO metformin. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"66"},{"groupId":"FG001","numSubjects":"71"},{"groupId":"FG002","numSubjects":"73"},{"groupId":"FG003","numSubjects":"70"},{"groupId":"FG004","numSubjects":"69"},{"groupId":"FG005","numSubjects":"71"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"66"},{"groupId":"FG002","numSubjects":"69"},{"groupId":"FG003","numSubjects":"63"},{"groupId":"FG004","numSubjects":"62"},{"groupId":"FG005","numSubjects":"56"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"15"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"10"}]},{"type":"Jury Duty","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Left the city to get a job","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"BG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"BG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"BG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"BG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"BG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"70"},{"groupId":"BG004","value":"69"},{"groupId":"BG005","value":"71"},{"groupId":"BG006","value":"420"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58.1","spread":"9.4"},{"groupId":"BG001","value":"59.0","spread":"8.5"},{"groupId":"BG002","value":"56.1","spread":"8.3"},{"groupId":"BG003","value":"55.6","spread":"8.4"},{"groupId":"BG004","value":"57.6","spread":"9.1"},{"groupId":"BG005","value":"56.5","spread":"9.7"},{"groupId":"BG006","value":"57.1","spread":"8.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"33"},{"groupId":"BG004","value":"32"},{"groupId":"BG005","value":"35"},{"groupId":"BG006","value":"199"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"47"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"36"},{"groupId":"BG006","value":"221"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"22"},{"groupId":"BG005","value":"22"},{"groupId":"BG006","value":"129"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"47"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"47"},{"groupId":"BG006","value":"264"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"27"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"8"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"25"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"59"},{"groupId":"BG003","value":"58"},{"groupId":"BG004","value":"59"},{"groupId":"BG005","value":"58"},{"groupId":"BG006","value":"348"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"38"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Greece","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"32"}]}]},{"title":"Puerto Rico","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"12"}]}]},{"title":"Romania","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"57"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"34"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"193"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"66"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"60"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","populationDescription":"All randomized participants with baseline and at least one post-baseline HbA1c data at Week 12. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HbA1c","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"63"},{"groupId":"OG005","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.07","spread":"0.12"},{"groupId":"OG001","value":"-1.09","spread":"0.11"},{"groupId":"OG002","value":"-1.44","spread":"0.11"},{"groupId":"OG003","value":"-1.33","spread":"0.11"},{"groupId":"OG004","value":"-1.42","spread":"0.11"},{"groupId":"OG005","value":"-0.29","spread":"0.11"}]}]}],"analyses":[{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"0.459","statisticalMethod":"Bayesian","paramType":"Posterior Mean Difference","paramValue":"-0.78","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.05","ciUpperLimit":"-0.52","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.16"},{"groupIds":["OG001","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"0.511","statisticalMethod":"Bayesian","paramType":"Posterior Mean Difference","paramValue":"-0.80","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.07","ciUpperLimit":"-0.54","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.16"},{"groupIds":["OG002","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"0.988","statisticalMethod":"Bayesian","paramType":"Posterior Mean Difference","paramValue":"-1.15","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.41","ciUpperLimit":"-0.89","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.16"},{"groupIds":["OG003","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"0.934","statisticalMethod":"Bayesian","paramType":"Posterior Mean Difference","paramValue":"-1.04","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.30","ciUpperLimit":"-0.78","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.16"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"0.373","statisticalMethod":"Bayesian","paramType":"Posterior Mean Difference","paramValue":"0.35","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.08","ciUpperLimit":"0.61","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.16"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"0.433","statisticalMethod":"Bayesian","paramType":"Posterior Mean Difference","paramValue":"0.33","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.07","ciUpperLimit":"0.59","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.16"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"0.978","statisticalMethod":"Bayesian","paramType":"Posterior Mean Difference","paramValue":"-0.02","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.28","ciUpperLimit":"0.24","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.16"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"0.904","statisticalMethod":"Bayesian","paramType":"Posterior Mean Difference","paramValue":"0.09","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.17","ciUpperLimit":"0.35","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.16"}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 24","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","populationDescription":"All randomized participants with baseline and at least one post-baseline HbA1c data at Week 24. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HbA1c","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"60"},{"groupId":"OG005","value":"51"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.85","spread":"0.14"},{"groupId":"OG001","value":"-1.14","spread":"0.13"},{"groupId":"OG002","value":"-1.37","spread":"0.13"},{"groupId":"OG003","value":"-1.29","spread":"0.13"},{"groupId":"OG004","value":"-1.48","spread":"0.13"},{"groupId":"OG005","value":"-0.38","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Body Weight","populationDescription":"All randomized participants with baseline and at least one post-baseline data for body weight. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percentage change","timeFrame":"Baseline, Week 12; Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"63"},{"groupId":"OG005","value":"63"}]}],"classes":[{"title":"Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"67"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"63"},{"groupId":"OG005","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.09","spread":"0.35"},{"groupId":"OG001","value":"-1.86","spread":"0.33"},{"groupId":"OG002","value":"-2.01","spread":"0.33"},{"groupId":"OG003","value":"-3.23","spread":"0.34"},{"groupId":"OG004","value":"-2.04","spread":"0.35"},{"groupId":"OG005","value":"-1.22","spread":"0.34"}]}]},{"title":"Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"60"},{"groupId":"OG005","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.57","spread":"0.47"},{"groupId":"OG001","value":"-2.13","spread":"0.45"},{"groupId":"OG002","value":"-1.98","spread":"0.45"},{"groupId":"OG003","value":"-3.41","spread":"0.46"},{"groupId":"OG004","value":"-2.18","spread":"0.47"},{"groupId":"OG005","value":"-1.70","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Blood Glucose","description":"Least square means (LSM) was calculated from mixed-effects model with repeated measures (MMRM) analysis using restricted maximum likelihood (REML) with metformin use, baseline body mass index (BMI) category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for fasting blood glucose. Missing observations are imputed using last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milligrams per deciliter (mg/dL)","timeFrame":"Baseline, Week 12; Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"-20.881","spread":"4.618"},{"groupId":"OG001","value":"-21.991","spread":"4.371"},{"groupId":"OG002","value":"-31.309","spread":"4.305"},{"groupId":"OG003","value":"-28.405","spread":"4.506"},{"groupId":"OG004","value":"-39.074","spread":"4.419"},{"groupId":"OG005","value":"-1.588","spread":"4.519"}]}]},{"title":"Week 24","categories":[{"measurements":[{"groupId":"OG000","value":"-21.497","spread":"4.919"},{"groupId":"OG001","value":"-30.186","spread":"4.639"},{"groupId":"OG002","value":"-29.875","spread":"4.548"},{"groupId":"OG003","value":"-31.390","spread":"4.785"},{"groupId":"OG004","value":"-40.328","spread":"4.726"},{"groupId":"OG005","value":"0.124","spread":"4.973"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values","description":"SMBG 7-point profiles were measured at morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. LSM were calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for SMBG. Missing observations are imputed using last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, Week (Wk) 12; Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"Morning pre-meal (Week 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-26.8","spread":"3.9"},{"groupId":"OG001","value":"-28.4","spread":"3.8"},{"groupId":"OG002","value":"-34.3","spread":"3.7"},{"groupId":"OG003","value":"-34.8","spread":"3.8"},{"groupId":"OG004","value":"-38.7","spread":"3.8"},{"groupId":"OG005","value":"-7.4","spread":"3.8"}]}]},{"title":"Morning pre-meal (Week 24)","categories":[{"measurements":[{"groupId":"OG000","value":"-23.5","spread":"4.7"},{"groupId":"OG001","value":"-29.1","spread":"4.5"},{"groupId":"OG002","value":"-29.6","spread":"4.3"},{"groupId":"OG003","value":"-34.2","spread":"4.5"},{"groupId":"OG004","value":"-36.8","spread":"4.5"},{"groupId":"OG005","value":"-14.4","spread":"4.9"}]}]},{"title":"Morning 2 hours post-meal (Week 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-27.9","spread":"6.7"},{"groupId":"OG001","value":"-34.2","spread":"6.8"},{"groupId":"OG002","value":"-36.0","spread":"6.3"},{"groupId":"OG003","value":"-26.4","spread":"6.6"},{"groupId":"OG004","value":"-43.5","spread":"6.5"},{"groupId":"OG005","value":"-1.5","spread":"6.5"}]}]},{"title":"Morning 2 hours post-meal (Week 24)","categories":[{"measurements":[{"groupId":"OG000","value":"-29.9","spread":"6.5"},{"groupId":"OG001","value":"-35.9","spread":"6.5"},{"groupId":"OG002","value":"-37.1","spread":"6.1"},{"groupId":"OG003","value":"-42.8","spread":"6.4"},{"groupId":"OG004","value":"-42.7","spread":"6.4"},{"groupId":"OG005","value":"-6.3","spread":"6.8"}]}]},{"title":"Mid-day pre-meal (Week 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-17.1","spread":"5.1"},{"groupId":"OG001","value":"-19.6","spread":"5.1"},{"groupId":"OG002","value":"-26.1","spread":"4.8"},{"groupId":"OG003","value":"-24.2","spread":"5.0"},{"groupId":"OG004","value":"-23.5","spread":"5.0"},{"groupId":"OG005","value":"-2.3","spread":"5.0"}]}]},{"title":"Mid-day pre-meal (Week 24)","categories":[{"measurements":[{"groupId":"OG000","value":"-16.3","spread":"5.6"},{"groupId":"OG001","value":"-23.4","spread":"5.6"},{"groupId":"OG002","value":"-22.4","spread":"5.3"},{"groupId":"OG003","value":"-23.5","spread":"5.4"},{"groupId":"OG004","value":"-23.9","spread":"5.5"},{"groupId":"OG005","value":"-4.0","spread":"6.0"}]}]},{"title":"Mid-day 2 hours post-meal (Week 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-17.1","spread":"6.4"},{"groupId":"OG001","value":"-20.7","spread":"6.3"},{"groupId":"OG002","value":"-24.6","spread":"6.0"},{"groupId":"OG003","value":"-22.2","spread":"6.2"},{"groupId":"OG004","value":"-27.4","spread":"6.2"},{"groupId":"OG005","value":"-8.9","spread":"6.1"}]}]},{"title":"Mid-day 2 hours post-meal (Week 24)","categories":[{"measurements":[{"groupId":"OG000","value":"-12.2","spread":"6.1"},{"groupId":"OG001","value":"-26.6","spread":"5.9"},{"groupId":"OG002","value":"-21.9","spread":"5.7"},{"groupId":"OG003","value":"-33.4","spread":"5.9"},{"groupId":"OG004","value":"-37.2","spread":"5.9"},{"groupId":"OG005","value":"-8.5","spread":"6.4"}]}]},{"title":"Evening pre-meal (Week 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-24.1","spread":"5.3"},{"groupId":"OG001","value":"-24.8","spread":"5.2"},{"groupId":"OG002","value":"-28.5","spread":"4.9"},{"groupId":"OG003","value":"-30.1","spread":"5.1"},{"groupId":"OG004","value":"-24.7","spread":"5.1"},{"groupId":"OG005","value":"-1.5","spread":"5.1"}]}]},{"title":"Evening pre-meal (Week 24)","categories":[{"measurements":[{"groupId":"OG000","value":"-24.9","spread":"5.7"},{"groupId":"OG001","value":"-24.3","spread":"5.6"},{"groupId":"OG002","value":"-33.0","spread":"5.3"},{"groupId":"OG003","value":"-29.6","spread":"5.4"},{"groupId":"OG004","value":"-36.4","spread":"5.6"},{"groupId":"OG005","value":"-5.7","spread":"6.0"}]}]},{"title":"Evening 2 hours post-meal (Week 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-25.1","spread":"5.9"},{"groupId":"OG001","value":"-26.5","spread":"5.7"},{"groupId":"OG002","value":"-33.4","spread":"5.4"},{"groupId":"OG003","value":"-32.8","spread":"5.7"},{"groupId":"OG004","value":"-33.5","spread":"5.7"},{"groupId":"OG005","value":"4.0","spread":"5.6"}]}]},{"title":"Evening 2 hours post-meal (Week 24)","categories":[{"measurements":[{"groupId":"OG000","value":"-30.2","spread":"5.9"},{"groupId":"OG001","value":"-27.9","spread":"5.8"},{"groupId":"OG002","value":"-26.0","spread":"5.5"},{"groupId":"OG003","value":"-37.2","spread":"5.8"},{"groupId":"OG004","value":"-36.9","spread":"5.8"},{"groupId":"OG005","value":"1.1","spread":"6.2"}]}]},{"title":"Bedtime (Week 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-19.3","spread":"5.7"},{"groupId":"OG001","value":"-33.5","spread":"5.8"},{"groupId":"OG002","value":"-33.2","spread":"5.8"},{"groupId":"OG003","value":"-36.2","spread":"5.6"},{"groupId":"OG004","value":"-41.6","spread":"5.7"},{"groupId":"OG005","value":"5.6","spread":"5.7"}]}]},{"title":"Bedtime (Week 24)","categories":[{"measurements":[{"groupId":"OG000","value":"-28.9","spread":"6.0"},{"groupId":"OG001","value":"-25.4","spread":"6.0"},{"groupId":"OG002","value":"-32.3","spread":"5.7"},{"groupId":"OG003","value":"-38.5","spread":"5.9"},{"groupId":"OG004","value":"-42.9","spread":"6.0"},{"groupId":"OG005","value":"-6.9","spread":"6.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lipids","description":"Change from baseline in high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C). LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant an a random effect.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for lipids. Missing observations are imputed using last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"HDL-C","categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"1.03"},{"groupId":"OG001","value":"0.92","spread":"0.98"},{"groupId":"OG002","value":"0.90","spread":"0.96"},{"groupId":"OG003","value":"1.04","spread":"1.01"},{"groupId":"OG004","value":"2.35","spread":"0.990"},{"groupId":"OG005","value":"2.17","spread":"1.04"}]}]},{"title":"Total Cholesterol","categories":[{"measurements":[{"groupId":"OG000","value":"-1.26","spread":"4.37"},{"groupId":"OG001","value":"-1.12","spread":"4.16"},{"groupId":"OG002","value":"-1.46","spread":"4.09"},{"groupId":"OG003","value":"-5.11","spread":"4.24"},{"groupId":"OG004","value":"-0.12","spread":"4.22"},{"groupId":"OG005","value":"7.32","spread":"4.40"}]}]},{"title":"Triglycerides","categories":[{"measurements":[{"groupId":"OG000","value":"-14.63","spread":"11.49"},{"groupId":"OG001","value":"-13.32","spread":"10.93"},{"groupId":"OG002","value":"-15.40","spread":"10.59"},{"groupId":"OG003","value":"-20.96","spread":"11.16"},{"groupId":"OG004","value":"-11.83","spread":"11.01"},{"groupId":"OG005","value":"10.61","spread":"11.58"}]}]},{"title":"LDL-C","categories":[{"measurements":[{"groupId":"OG000","value":"-1.37","spread":"3.75"},{"groupId":"OG001","value":"-0.40","spread":"3.57"},{"groupId":"OG002","value":"-0.24","spread":"3.56"},{"groupId":"OG003","value":"-0.04","spread":"3.72"},{"groupId":"OG004","value":"0.37","spread":"3.65"},{"groupId":"OG005","value":"4.55","spread":"3.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Fibroblast Growth Factor 21","description":"LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for fasting fibroblast growth factor 21. Missing observations are imputed using last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"microgram per liter (µg/L)","timeFrame":"Baseline, Week 12; Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.071"},{"groupId":"OG001","value":"0.06","spread":"0.068"},{"groupId":"OG002","value":"-0.03","spread":"0.068"},{"groupId":"OG003","value":"-0.14","spread":"0.069"},{"groupId":"OG004","value":"-0.09","spread":"0.069"},{"groupId":"OG005","value":"-0.11","spread":"0.071"}]}]},{"title":"Week 24","categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.071"},{"groupId":"OG001","value":"-0.04","spread":"0.068"},{"groupId":"OG002","value":"-0.07","spread":"0.067"},{"groupId":"OG003","value":"-0.12","spread":"0.070"},{"groupId":"OG004","value":"-0.06","spread":"0.069"},{"groupId":"OG005","value":"-0.09","spread":"0.073"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Rescue Therapy","description":"Participants who received rescue medication with non-study antihyperglycemic medications or change their stable dose of metformin.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for participants requiring rescue therapy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through Therapy Completion (Week 24)","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1"},{"groupId":"OG001","value":"2.8"},{"groupId":"OG002","value":"2.7"},{"groupId":"OG003","value":"4.3"},{"groupId":"OG004","value":"2.9"},{"groupId":"OG005","value":"11.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Developing Anti-Drug Antibodies to LY2944876","description":"Percentage of participants developing anti-drug antibodies to LY2944876.","populationDescription":"All randomized participants who received study drug and had evaluable immunogenicity.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 12 and Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"70"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"64"},{"groupId":"OG005","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"1.4"},{"groupId":"OG002","value":"1.5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"63"},{"groupId":"OG005","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1.5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2944876","description":"Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.","populationDescription":"All randomized participants who received study drug LY2944876 and had evaluable PK data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"Baseline, Week 8, Week 12, Week 16, Week 20, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"607","spread":"282"},{"groupId":"OG001","value":"799","spread":"368"},{"groupId":"OG002","value":"1690","spread":"732"},{"groupId":"OG003","value":"2570","spread":"1240"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2944876","description":"Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.","populationDescription":"All randomized participants who received study drug LY2944876 and had evaluable PK data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms*hour per milliliter (ng*h/mL)","timeFrame":"Baseline, Week 8, Week 12, Week 16, Week 20, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88100","spread":"40600"},{"groupId":"OG001","value":"117000","spread":"50800"},{"groupId":"OG002","value":"247000","spread":"106000"},{"groupId":"OG003","value":"381000","spread":"187000"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Adiponectin Levels","description":"LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for adiponectin levels. Missing observations are imputed using last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"µg/L","timeFrame":"Baseline, Week 12; Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.168"},{"groupId":"OG001","value":"0.03","spread":"0.160"},{"groupId":"OG002","value":"-0.10","spread":"0.157"},{"groupId":"OG003","value":"0.12","spread":"0.161"},{"groupId":"OG004","value":"0.04","spread":"0.160"},{"groupId":"OG005","value":"0.03","spread":"0.164"}]}]},{"title":"Week 24","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.245"},{"groupId":"OG001","value":"0.30","spread":"0.226"},{"groupId":"OG002","value":"0.28","spread":"0.221"},{"groupId":"OG003","value":"0.58","spread":"0.235"},{"groupId":"OG004","value":"0.14","spread":"0.231"},{"groupId":"OG005","value":"0.25","spread":"0.250"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Beta-Hydroxy Butyrate Levels","description":"LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for beta-hydroxy butyrate levels. Missing observations are imputed using last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, Week 12; Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.13"},{"groupId":"OG001","value":"-0.28","spread":"0.12"},{"groupId":"OG002","value":"-0.13","spread":"0.12"},{"groupId":"OG003","value":"-0.31","spread":"0.12"},{"groupId":"OG004","value":"-0.29","spread":"0.12"},{"groupId":"OG005","value":"-0.23","spread":"0.13"}]}]},{"title":"Week 24","categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.11"},{"groupId":"OG001","value":"-0.39","spread":"0.10"},{"groupId":"OG002","value":"-0.34","spread":"0.10"},{"groupId":"OG003","value":"-0.33","spread":"0.10"},{"groupId":"OG004","value":"-0.19","spread":"0.10"},{"groupId":"OG005","value":"-0.37","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glucagon Levels","description":"LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for glucagon levels. Missing observations are imputed using last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"picomol per liter (pmol/L)","timeFrame":"Baseline, Week 12; Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"-1.26","spread":"0.82"},{"groupId":"OG001","value":"-2.65","spread":"0.79"},{"groupId":"OG002","value":"-5.14","spread":"0.79"},{"groupId":"OG003","value":"-6.21","spread":"0.81"},{"groupId":"OG004","value":"-1.58","spread":"0.79"},{"groupId":"OG005","value":"-0.04","spread":"0.84"}]}]},{"title":"Week 24","categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"1.15"},{"groupId":"OG001","value":"-2.25","spread":"1.05"},{"groupId":"OG002","value":"-4.40","spread":"1.05"},{"groupId":"OG003","value":"-4.93","spread":"1.11"},{"groupId":"OG004","value":"-0.19","spread":"1.08"},{"groupId":"OG005","value":"0.66","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Insulin Levels","description":"LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.","populationDescription":"All randomized participants with baseline and at least one post-baseline data for insulin levels. Missing observations are imputed using last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"micro-international units/milliliter","timeFrame":"Baseline, Week 12; Baseline, Week 24","groups":[{"id":"OG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks."},{"id":"OG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks."},{"id":"OG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks."},{"id":"OG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"71"}]}],"classes":[{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.21"},{"groupId":"OG001","value":"0.97","spread":"1.13"},{"groupId":"OG002","value":"0.03","spread":"1.14"},{"groupId":"OG003","value":"0.96","spread":"1.17"},{"groupId":"OG004","value":"2.78","spread":"1.14"},{"groupId":"OG005","value":"-0.85","spread":"1.16"}]}]},{"title":"Week 24","categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"1.51"},{"groupId":"OG001","value":"0.68","spread":"1.39"},{"groupId":"OG002","value":"0.58","spread":"1.40"},{"groupId":"OG003","value":"0.34","spread":"1.48"},{"groupId":"OG004","value":"1.97","spread":"1.40"},{"groupId":"OG005","value":"1.45","spread":"1.51"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"All randomized participants who received at least 1 dose of study drug.","eventGroups":[{"id":"EG000","title":"10 mg LY2944876","description":"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.","seriousNumAffected":0,"seriousNumAtRisk":66,"otherNumAffected":34,"otherNumAtRisk":66},{"id":"EG001","title":"15 mg LY2944876","description":"15 mg LY2944876 given SC once weekly for 24 weeks.","seriousNumAffected":2,"seriousNumAtRisk":71,"otherNumAffected":47,"otherNumAtRisk":71},{"id":"EG002","title":"30 mg LY2944876","description":"30 mg LY2944876 given SC once weekly for 24 weeks.","seriousNumAffected":2,"seriousNumAtRisk":73,"otherNumAffected":39,"otherNumAtRisk":73},{"id":"EG003","title":"50 mg LY2944876","description":"50 mg LY2944876 given SC once weekly for 24 weeks.","seriousNumAffected":3,"seriousNumAtRisk":70,"otherNumAffected":46,"otherNumAtRisk":70},{"id":"EG004","title":"Exenatide Extended-release","description":"2 mg exenatide extended-release given SC once weekly for 24 weeks.","seriousNumAffected":3,"seriousNumAtRisk":69,"otherNumAffected":38,"otherNumAtRisk":69},{"id":"EG005","title":"Placebo","description":"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.","seriousNumAffected":2,"seriousNumAtRisk":71,"otherNumAffected":16,"otherNumAtRisk":71}],"seriousEvents":[{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Branchial cyst","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":71}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Endometrial adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Endometrial cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Blood blister","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Cataract operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Vessel perforation","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":71}]}],"otherEvents":[{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG002","numEvents":7,"numAffected":2,"numAtRisk":73},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":70},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":69},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":71}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":71},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":73},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":70},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":71}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":7,"numAtRisk":66},{"groupId":"EG001","numEvents":24,"numAffected":15,"numAtRisk":71},{"groupId":"EG002","numEvents":45,"numAffected":13,"numAtRisk":73},{"groupId":"EG003","numEvents":25,"numAffected":12,"numAtRisk":70},{"groupId":"EG004","numEvents":52,"numAffected":18,"numAtRisk":69},{"groupId":"EG005","numEvents":16,"numAffected":4,"numAtRisk":71}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":73},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":70},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":73},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":70},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":11,"numAtRisk":66},{"groupId":"EG001","numEvents":33,"numAffected":21,"numAtRisk":71},{"groupId":"EG002","numEvents":53,"numAffected":20,"numAtRisk":73},{"groupId":"EG003","numEvents":90,"numAffected":32,"numAtRisk":70},{"groupId":"EG004","numEvents":55,"numAffected":17,"numAtRisk":69},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":71}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":66},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":71},{"groupId":"EG002","numEvents":21,"numAffected":10,"numAtRisk":73},{"groupId":"EG003","numEvents":37,"numAffected":22,"numAtRisk":70},{"groupId":"EG004","numEvents":12,"numAffected":6,"numAtRisk":69},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":71}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":73},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":71},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":71}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":66},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":71},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":73},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":70},{"groupId":"EG004","numEvents":7,"numAffected":6,"numAtRisk":69},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":71}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":71},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":73},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":71}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":71},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":73},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":70},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":69},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":71}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":73},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":71},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":73},{"groupId":"EG003","numEvents":9,"numAffected":5,"numAtRisk":70},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":71},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":73},{"groupId":"EG003","numEvents":9,"numAffected":8,"numAtRisk":70},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":71}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":70},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":71}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":71},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":69},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":71}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":71},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":71}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":66},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":71},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":73},{"groupId":"EG003","numEvents":11,"numAffected":6,"numAtRisk":70},{"groupId":"EG004","numEvents":14,"numAffected":9,"numAtRisk":69},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":71}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":71},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":69},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":71}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","removedCountries":["Spain"]},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D015431","term":"Weight Loss"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D001836","term":"Body Weight Changes"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D008687","term":"Metformin"}],"ancestors":[{"id":"D001645","term":"Biguanides"},{"id":"D006146","term":"Guanidines"},{"id":"D000578","term":"Amidines"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}